ACRV
Acrivon Therapeutics, Inc. · Healthcare · Market cap $75.4M
Insiders sold $40K net in the last 90 days ·6 sellers, 0 buyers· latest Form 4 filed Oct 7, 2026
Insider Buying
$114K
reported purchases (SEC code P)
Insider Selling
$40K
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Oct 7, 2026
Miller Mary
Acrivon Therapeutics, Inc. (ACRV) has 48 SEC Form 4 filings (53 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
Inside the rolling window, 6 insiders at Acrivon Therapeutics, Inc. reported 3 open-market purchases totaling $114K and 9 open-market sales totaling $40K. The most active filer is Chief Legal Officer Miller Mary with 3 filings. The most recent open-market filing is a sale of 294 shares by Chief Legal Officer Miller Mary, dated Oct 5, 2026, worth $585.
- Industry:Biotechnology
- CEO:Peter Blume-Jensen
- Employees:75
- HQ:Watertown, MA, US
- IPO:2022-11-15
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Legal Officer | Sale | 294 | $585 | Oct 7 | -6.4% | SEC ↗ | |
| President and CEO | Sale | 14,036 | $31K | Aug 27 | -18.1% | SEC ↗ | |
Blume-Jensen PeterFirst in 7 months | President and CEO | Sale | 1,713 | $3K | Aug 20 | -20.0% | SEC ↗ |
| Chief Legal Officer | Sale | 185 | $372 | Aug 20 | -20.0% | SEC ↗ | |
Peterson KatharineFirst filing | Chief Accounting Officer | Sale | 101 | $203 | Aug 20 | -20.0% | SEC ↗ |
Devroe EricFirst in 7 months | Chief Operating Officer | Sale | 604 | $1K | Aug 20 | -20.0% | SEC ↗ |
Gamelin ErickFirst filing | Chief Development Officer | Sale | 400 | $804 | Aug 20 | -20.0% | SEC ↗ |
Levy Adam D.First in 7 months | Chief Financial Officer | Sale | 1,142 | $2K | Aug 6 | +4.1% | SEC ↗ |
Miller MaryFirst filing | Chief Legal Officer | Sale | 573 | $1K | Jul 23 | +5.4% | SEC ↗ |
Levy Adam D.First filing | Chief Financial Officer | Purchase | 8,832 | $15K | Jan 16 | — | SEC ↗ |
Blume-Jensen PeterFirst filing | President and CEO | Purchase | 49,000 | $82K | Jan 16 | — | SEC ↗ |
Devroe EricFirst filing | Chief Operating Officer | Purchase | 10,000 | $17K | Jan 15 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does ACRV have?
Acrivon Therapeutics, Inc. (ACRV) has 48 SEC Form 4 filings (53 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Oct 7, 2026.
When was the most recent SEC Form 4 filing for ACRV?
The most recent Form 4 filing for ACRV on Tracefour is dated Oct 7, 2026.
Who is the most active insider at ACRV?
The most active SEC Form 4 filer at ACRV in the rolling window is Chief Legal Officer Miller Mary, with 3 filings.
What is the net insider flow at ACRV over the last 6 months?
Over the trailing 180 days, insiders at ACRV have net sold $40K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ACRV in the current window?
Inside the rolling window, insiders at ACRV bought $114K and sold $40K based on SEC Form 4 filings.
Can I get alerts for ACRV insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Acrivon Therapeutics, Inc. (ACRV). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Acrivon Therapeutics, Inc. is in the Healthcare sector.